drugset / Trial / NCT01831726
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
Timeline
- Start
- 2013-08
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dovitinib | Small molecule | 500 mg | — |
Indications
No indication recorded.